Targeting the KRAS mutation for more effective cancer treatment | MD Anderson Cancer Center
Frontiers | Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
A saturation mutagenesis screen uncovers resistant and sensitizing secondary KRAS mutations to clinical KRASG12C inhibitors | PNAS
The current state of the art and future trends in RAS-targeted cancer therapies | Nature Reviews Clinical Oncology
Partnership seeks to develop KRAS degraders for cancer therapy | Frederick National Laboratory
Frontiers | Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
Targeting Mutant KRAS for Immunogenic Cell Death Induction: Trends in Pharmacological Sciences
IJMS | Free Full-Text | KRAS-Mutant Non-Small-Cell Lung Cancer: From Past Efforts to Future Challenges
KRAS Biomarker | Colorectal Cancer Alliance
Frontiers | The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures
Partnership seeks to develop KRAS degraders for cancer therapy | Frederick National Laboratory
KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition - eBioMedicine
JCM | Free Full-Text | KRAS Mutations in Solid Tumors: Characteristics, Current Therapeutic Strategy, and Potential Treatment Exploration
KRAS inhibitors, approved | Nature Cancer
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC) - ScienceDirect
Somatic Gain of KRAS Function in the Endothelium Is Sufficient to Cause Vascular Malformations That Require MEK but Not PI3K Signaling | Circulation Research
Notorious KRAS: Taking down cancer researchers' biggest foe
Frontiers | Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer
KRAS: feeding pancreatic cancer proliferation: Trends in Biochemical Sciences
KRAS: Kirsten RAT Sarcoma Viral Oncogenic Homolog
Development and Preclinical Evaluation of Radiolabeled Covalent G12C-Specific Inhibitors for Direct Imaging of the Oncogenic KRAS Mutant | Molecular Pharmaceutics
Chemically modified MIR143-3p exhibited anti-cancer effects by impairing the KRAS network in colorectal cancer cells: Molecular Therapy - Nucleic Acids
KRAS - Wikipedia
Cureus | KRAS/NRAS/BRAF Mutation Rate in Saudi Academic Hospital Patients With Colorectal Cancer | Article
Targeted Therapy for 'Undruggable' Lung Cancer Stems from Decades of UCSF Research | UC San Francisco
KRAS mutation identified in a patient with melorheostosis and extended lymphangiomatosis treated with sirolimus and trametinib - Lacasta‐Plasin - 2021 - Clinical Genetics - Wiley Online Library
KRAS mutation: from undruggable to druggable in cancer | Signal Transduction and Targeted Therapy
Precision oncology provides opportunities for targeting KRAS-inhibitor resistance: Trends in Cancer
